August 2016 – Page 6

Grand View Research – August 2016

The global spinal implants and spinal devices market is expected to reach over USD 19.54 billion by 2024 according to a new report by Grand View Research, Inc.

The key drivers of the market include the rising number of spinal injuries, increasing trend in the adoption of sedentary lifestyles, postural defects stemming from bad posture habits at work and while driving, and a large number of people suffering from obesity. In addition to the above, the introduction of the image-based spinal navigation technology, the evolution of titanium biologics, and the ongoing research on the genetically modified bone morphogenetic proteins are also expected to positively reinforce the market growth.

Moreover, the increase in the geriatric population base prone to spinal disorders due to the lack of proper diet and exercise and declining bone density are also expected to fuel the market expansion over the forecast period.

The rising cost of spinal implants and procedural costs are a major concern across the globe and this factor is identified as a large strain on the emerging and low-income economies. Therefore, the introduction of novel bone growth stimulators and the increasing adoption of Minimally-Invasive Surgeries (MIS) surgeries that are relatively less-expensive are expected to propel the usage of spinal implants and devices over the forecast period.

With favorable government initiatives being advanced and the increasing number of investments being made by various private organizations is providing the thrust to the R&D activities pertaining to new product development and new treatment methods.

For instance, the American Academy of Orthopedic Surgeons and the North American Spine Foundation, both contribute towards the growth of the spinal implants and devices market through R&D funding activities and training programs for physicians globally.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/spinal-implants-spinal-devices-market

Further key findings from the study suggest:

In 2015, the spinal fusion devices segment accounted for the largest share of over 38% as these are the most commonly used devices for the treatment of various conditions, such as spine stenosis, spondylolisthesis, and scoliosis. However, the spinal biologics segment is expected to emerge as the fastest growing with a CAGR of 7% due to the growing usage of minimally invasive and non-invasive procedures.
In 2015, North America held the largest share of the spinal implants and devices market accounting for nearly 63%. The presence of advanced healthcare facilities, strong reimbursement support, and a large number of people suffering with spinal disorders are some of the major factors accounting for this region’s dominance.
Asia Pacific is expected to be the fastest growing market due to the proliferation of the latest medical technologies andthe development of low-cost implants coupled with the growing medical coverage and the increasing per capita disposable income. Moreover, the growing support from the government to expand the healthcare services in the untapped markets is also expected to propel the market growth in this region.
Some key players operating in the market are Medtronic plc, Depuy Synthes, Inc., Stryker Corporation, NuVasive, Inc., Zimmer Biomet Holdings, Inc., Globus Medical, Inc., Orthofix International Holding N.V., and LDR Holding Corporation.

Grand View Research has segmented the global spinal implants and spinal devices market on the basis of product, technology, type of surgery, and type of procedure:

Global Spinal Implants and Devices Market Product Outlook, by Revenue (USD Billion, 2016 – 2024)

Spinal Fusion devices
Spinal biologics
Vertebral compression fracture treatment devices
Non-fusion devices
Spinal bone growth stimulators

Global Spinal Implants And Devices Market Technology Outlook, By Revenue (USD Billion, 2016 – 2024)

Fusion and fixation technology
Vertebral compression fracture treatment
Motion preservation technologies

Global Spinal Implants And Devices Market Type Of Surgery Outlook, By Revenue (USD Billion, 2016 – 2024)

Open surgery
Minimally invasive surgery

Global Spinal Implants And Spinal Market Procedure Type Outlook, By Revenue (USD Billion, 2016 – 2024)

Discectomy
Laminotomy
Foraminotomy
Facetectomy
Corpectomy

Spinal Implants and Spinal Market Regional Outlook, by Revenue (USD Billion, 2016 – 2024)

North America
- U.S.
- Canada
Europe
- UK
- Germany
Asia Pacific
- Japan
- China
Latin America
- Brazil
- Mexico
MEA
- South Africa

August 22, 2016

Cincinnati, OH /PRNewswire/ – Ethicon^*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.

STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.

“I call it the suture of the future,” said James Dan Kondrup^**, M.D., Minimally Invasive Gynecologic Surgeon of Lourdes Hospital in Binghamton, NY. “Any case where I can use STRATAFIX sutures, I will.”

The versatile STRATAFIX™ portfolio of knotless sutures will help surgeons to achieve the optimal clinical outcome for each tissue type, from skin and fat layers to fascia^*** and organs. STRATAFIX™ Spiral Plus sutures boast exceptional wound holding strength while offering a smooth glide through tissue, and are available in both bidirectional and a unidirectional design with an adjustable fixation loop. These new sutures are made with proprietary polymers, premium needles and Plus antibacterial coating that continue to deliver the optimal wound closure experience surgeons and health care practitioners expect from Ethicon.

“With more than 60 years of experience, Ethicon has become synonymous with surgical sutures,” said Liza Ovington, Franchise Medical Director for Ethicon. “Ethicon will continue to innovate in wound closure working to provide solutions that elevate the standard of care for surgeons and the patients they serve.”

STRATAFIX™ Knotless Tissue Control Devices can address tissue repair needs in a broad range of surgical specialties including orthopaedic, plastic, gynecological, general, bariatric, colorectal, and urological procedures. Additional information about the Ethicon STRATAFIX™ portfolio can be found here:

http://www.ethicon.com/healthcare-professionals/products/wound-closure/tissue-control-devices

About Ethicon^*
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing health care issues, and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon.

^*Ethicon, Inc. is the legal manufacturer of STRATAFIX™ Sutures.
^**James Kondrup is a paid consultant of Ethicon.
^***Fascia indication for STRATAFIX™ Symmetric PDS™ Plus only.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

SOURCE: Ethicon

AUSTIN, Texas, Aug. 22, 2016 /PRNewswire/ — Celling Biosciences, the foremost pioneer in point-of-care cell therapies, is opening an international office in Curitiba, Brazil, one of the largest medical markets in the world. Combined with Mexican sales that continue to grow, company leaders are confident that this new office will build a bright future for cell therapies in all of South America.

The international development team will continue discussions with Ireland to manage the European expansion. Celling Dubai’s office has yielded information indicating that cell therapy will be well received in the Dubai and East Asian markets.

Kevin Dunworth, CEO of Celling Biosciences, said, “We’re very excited about this opportunity, and the timing could not be better with the world’s attention focused on the athletes in Rio for the Olympics. I personally started my career internationally in Europe, the Middle East, and South America. So this is a little like coming home for me. Though it took more time than I wanted, the technology we now offer has been well vetted in our own market, and I’m thrilled to bring it to the international stage in a place like Brazil.”

While the Brazil office will enter Celling’s traditional markets of orthopedics and spine, company representatives say they are excited to continue developing their faster growing segments of pain management and cosmesis. According to Andre Luiz Macias, managing partner of Celling Brazil, “We are very excited about not only the sports medicine applications but also believe the aesthetics opportunity is one of the largest in the world. We have been working closely with the research and development team in Austin, Texas to educate ourselves on the latest technologies for processing and delivering cells to the patient. Our objective is to take the ongoing effort in the U.S. and deliver the same education and scientific excellence to the physicians and patients across Brazil.”

Celling Brazil will follow the North American model of relying heavily upon a team of highly trained scientists to educate physicians on the ever expanding potential of autologous cell therapies. The research team has expressed excitement about the incredible opportunity to do clinical studies in Brazil across a wide spectrum of applications including critical limb ischemia, sports related injuries, and procedures for cosmetic rejuvenation of the skin.

Celling Biosciences Brazil
Managing Partner: Andre Luiz Macias
Av. Sete de setembro, 5402 , sala 75
Curitiba – Paraná – Brasil
80240-000

Contact:
Steve Melchiode
smelchiode@cellingbiosciences.com

Photo – http://photos.prnewswire.com/prnh/20160819/399667

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celling-biosciences-opens-international-office-in-brazil-300316539.html

PITTSBURGH, April 22 /PRNewswire/ — Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.

Flexuspine’s FSU Total Spinal Segment Replacement is designed to provide an alternative to fusion by reestablishing mobility in an affected segment of the lumbar spine. The device is composed of an interbody disc component (Core) and posterior dynamic resistance component (Dampener) and is designed as a system to restore the motion and natural kinematics of the affected spine segment.

The approval process included an extensive review of Flexuspine’s research, design and biomechanical testing of the FSU device by the FDA, as well as an assessment of Dr. Louis Nel Jr.‘s first-in-man clinical series performed inSouth Africa. “This is a much needed next step in spinal arthroplasty. The potential advantages of this technology could make it the first real ‘total’ level replacement,” commented Dr. Nel.

“The FSU is not like the currently approved disc or facet replacement devices on the market today that only partially rebuild the motion segment. The FSU has three separate parts working together, similar to healthy discs and facets, and is designed to achieve segmental reconstruction from a single posterior approach,” declared Erik Wagner, Chief Technical Officer.

“We are extremely proud of reaching this milestone after completing the tremendous amount of work that went into the development of the FSU device. We are moving into this next phase of our business to verify and validate the science and technology behind the product,” stated Vincent Jannetty, President and CEO of Flexuspine.

“We also just recently received multiple ‘notices of allowance of claims’ from the U.S. Patent and Trademark Office. We are very pleased that these claims cover both the system and key features of the product. This recognition by the patent office of the novelty of the system along with the launch of the clinical study, create the solid business foundation we have been working towards,” continued Jannetty.

Flexuspine plans to begin patient enrollment in the U.S. feasibility study soon while continuing to establish similar clinical study sites in several countries outside the U.S. The goal of these international studies was, and still is, to collect additional data that may be used in support of a U.S. Pivotal Clinical Trial.

About Flexuspine

Flexuspine is a privately held spine company based in Pittsburgh, PA. Flexuspine is dedicated to the sole focus of pioneering the field of total spine arthroplasty by developing the FSU device as an alternative to lumbar fusion. For more information on Flexuspine please visit www.flexuspine.com.

SOURCE Flexuspine, Inc.

RELATED LINKS

http://www.flexuspine.com

WARSAW, Ind., Aug. 23, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2016.

The cash dividend of $0.24 per share will be paid on or about October 28, 2016 to stockholders of record as of the close of business on September 23, 2016. Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Logo – http://photos.prnewswire.com/prnh/20150624/225371LOGO

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

Written By John Overall – August 22, 2016

TUCSON – The first hip replacement surgery was performed in 1960. Now, more than 300,000 total hip replacements are performed each year in the United States.

Dr. Russell Cohen from the Tucson Orthopaedic Institute joined a team of other surgeons to develop a new surgical technique that allows their patients to get back on their feet sooner.

59-year-old Mindy Sparks suffers from severe arthritis in her hips. About six months ago the pain became unbearable, “I would walk across a parking lot and almost feel like crying it hurt so badly,” Sparks said.

Dr. Cohen showed News 4 Tucson Mindy’s X-Rays, “You can see here that her hip joint is completely gone. There’s no separation between the ball and the socket. So these two hips are about as bad as a hip needs to be before we recommend it be replaced,” Dr. Cohen said.

Dr. Cohen has been performing minimally invasive hip and knee replacements since 2003. About three years ago Dr. Cohen joined six other surgeons and came up with a procedure they call The Direct Superior Approach to the hip.

READ THE REST HERE

By: Norbert Sparrow | PLASTEC Minneapolis

One of the rightly touted breakthroughs of 3D printing in the medical space is the technology’s capability of producing custom orthopedic devices that precisely match specific patient anatomies. University of Minnesota mechanical engineering professor Michael McAlpine wants to take that a step further by integrating customized functionality into the 3D-printed device.

“The big value in 3D printing is customization not just of the geometry but also the functionality,” McAlpine told PlasticsToday. “That means building in function from various materials that also may be specific to what the patient needs.” He and fellow researchers have taken a big step in that direction with a 3D-printed silicone guide embedded with proteins to enable nerve regeneration. The technique has been shown to be successful in regenerating the sciatic nerve in rats.

Nerve regeneration in and of itself is a complex process, and that is compounded by the y-shaped geometry of the sciatic nerve, which branches out as it travels down the leg. “A damaged sciatic nerve is difficult, if not impossible, to repair,” says McAlpine. Through the use of a 3D scanner and custom designed 3D printer that allows integration of multiple materials, including plastics, cells and functional materials such as electronic and semiconducting nanoparticles and hydrogels, on the same platform, McAlpine’s team was able to print custom nerve guides that promote both motor and sensory nerve regeneration.

READ THE REST HERE

TAMPA, Fla.–(BUSINESS WIRE)–ForeSight Medical has launched Encompass Specialty Surgical Network, a specialized orthopedic, spine and pain management surgical network for workers’ compensation payers.

The leading provider of surgical device cost containment in workers’ compensation, ForeSight leveraged its deep domain experience and extensive surgical data and analytics platform to develop the first narrow network of best-in-class providers, world renowned physician groups and the ambulatory surgical centers that are customized for their surgical techniques.

“Ambulatory surgical centers are the safest and most efficient sites of care for most workers’ compensation related surgeries,” said ForeSight President Brian Bell. “However, legacy networks typically focus on broad-based facility agreements, which inadvertently drive over 70 percent of injured employees’ surgeries into a less efficient, cost-prohibitive site of care, the hospital.”

Encompass manages surgery from the initial surgical consultation through discharge, streamlining authorization, reserve-setting, scheduling, patient relations, billing, and payment processing. Encompass utilizes a proprietary scoring system to ensure patients see the highest quality, most responsible providers early in the treatment path to ensure the best outcome. Surgical Care Coordinators schedule the procedure with a top quality surgeon who has privileges at an in-network ambulatory surgical center. These coordinators proactively support all aspects of patient care and customer service. An advanced outcomes reporting platform delivers actionable analytics to medical managers, including comprehensive savings, outcomes and provider performance metrics.

The industry’s first specialty surgery management organization, Encompass focuses on the quality of surgical outcomes, lower surgical revision rates and off-label utilization, and post-operative medical expenses that reduce return-to-work rates. “Encompass will deliver unmatched savings, superior patient outcomes and actionable reporting,” Bell said, noting that the company is uniquely positioned to thrive in this space.

In addition to its vast, true-cost, geo-specific surgical data, Encompass has a management team with 50 combined years of experience in the surgical care continuum. The team’s profound understanding of administration, clinician and site-of care dynamics enhances a payer’s ability to manage costs and surgical outcomes.

For more information, please contact Encompass 844-427-4251 or visit www.encompasssurgicalnetwork.com.

About Encompass Specialty Surgical Network

Developed by a team of ambulatory surgical center and implantable device experts, Encompass enhances payers’ ability to manage cost and surgical outcomes by directing eligible surgical candidates to the most qualified physicians early in the care continuum. Using data, analytics and quality based scoring metrics, Encompass delivers unmatched value for the highest acuity and highest cost patient care and is changing the way surgery is managed. It is the industry’s first surgical management organization that delivers cost effective, patient-focused, quality outcomes in the ambulatory surgical center setting.

Contacts

King Knight Communications
Helen Patterson, 813-690-4787
helen@kingknight.com

Newer Posts

Search

3 days / 6 sessions
Current Issues in Spine

Spinal Implants and Devices Market Worth $19.5 Billion by 2024

Ethicon Establishes Unmatched Knotless Suture Portfolio With Launch Of Stratafix™ Spiral Plus Devices

Celling Biosciences Opens International Office in Brazil

Flexuspine Receives FDA Conditional Approval to Begin a Feasibility Study of Its FSU (Functional Spinal Unit) Total Spine Arthroplasty System in the United States

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2016

Tucson Orthopaedic surgeon helps invent new hip replacement procedure

The future of medical 3D printing

ForeSight Medical Announces the Launch of Encompass

Contacts

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS